ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00051493

Enrollment

Registered

2003-01-14

Start date

2002-04-30

Completion date

2002-12-31

Last updated

2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer

Brief summary

The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.

Interventions

DRUGALIMTA

DRUGCarboplatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* You have a diagnosis of non-small cell lung cancer. * You have received no prior chemotherapy. * You have at least one measurable lesion. * You have an adequate performance status. * You are at least 18 years of age.

Exclusion criteria

* You have previously received chemotherapy for your lung cancer. * You have received radiation within the last 30 days. * You have active infection or other serious condition. * You have brain metastasis. * You have recently lost a significant amount of weight.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026